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ABSTRACT
African-Americans are diagnosed with more aggressive prostate cancers and 
have worse survival than Caucasians, however a comprehensive understanding of this 
health disparity remains unclear. To clarify the mechanisms leading to this disparity, 
we analyzed the potential involvement of miR-34b expression in African-Americans 
and Caucasians. miR-34b functions as a tumor suppressor and has a multi-functional 
role, through regulation of cell proliferation, cell cycle and apoptosis. We found that 
miR-34b expression is lower in human prostate cancer tissues from African-Americans 
compared to Caucasians. DNA hypermethylation of the miR-34b-3p promoter region 
showed significantly higher methylation in prostate cancer compared to normal 
samples. We then sequenced the promoter region of miR-34b-3p and found a 
chromosomal deletion in miR-34b in African-American prostate cancer cell line (MDA-
PCA-2b) and not in Caucasian cell line (DU-145). We found that AR and ETV1 genes 
are differentially expressed in MDA-PCa-2b and DU-145 cells after overexpression of 
miR-34b. Direct interaction of miR-34b with the 3’ untranslated region of AR and ETV1 
was validated by luciferase reporter assay. We found that miR-34b downregulation in 
African-Americans is inversely correlated with high AR levels that lead to increased 
cell proliferation. Overexpression of miR-34b in cell lines showed higher inhibition 
of cell proliferation, apoptosis and G1 arrest in the African-American cells (MDA-
PCa-2b) compared to Caucasian cell line (DU-145). Taken together, our results show 
that differential expression of miR-34b and AR are associated with prostate cancer 
aggressiveness in African-Americans.
INTRODUCTION
Prostate cancer (PCa) is the most commonly 
diagnosed cancer in American men and is the second 
leading cause of cancer mortality in the United States. 
African-Americans have the world’s highest incidence of 
PCa and the mortality rate is more than two times greater 
than Caucasian men [1, 2]. This racial disparity has been 
attributed to differences in tumor growth rates, disease 
aggressiveness and genetic variants [3, 4]. Elucidating 
the mechanisms underlying these disparities is of crucial 
importance in reducing the incidence of prostate cancer in 
African-American males.
Androgen receptor (AR) signaling has been reported 
to have a critical role associated with prostate cancer in 
racial disparities [5, 6]. Studies show that AR expression 
was 22% higher in the benign prostate and 81% higher 
in prostate cancer of African-Americans compared to 
Caucasians [6]. The AR gene is located at Xq11.2-q12 
(markers DXS991-DXS983) and is more than 90 kb in 
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length. The amino-terminal domain is encoded by exon 
one, which includes highly polymorphic CAG repeats 
[7]. A previous study showed that Caucasian, African-
American and Asian subjects predicted an increased risk of 
prostate cancer in men with short (≤21) CAG repeats [8]. 
Other studies found no association between the AR CAG 
repeat length and prostate cancer risk [9]. Evidence that 
AR CAG repeat length is associated with prostate cancer 
risk remains controversial [8]. ETV1 is overexpressed 
in 5–10% of prostate cancers [10]. Tomlins et al. [11] 
identified recurrent genomic rearrangements in prostate 
cancer resulting in the fusion of the 5′ untranslated end 
of TMPRSS2 (a prostate-specific, androgen-responsive, 
transmembrane serine protease gene) to ETS family 
members (ERG, ETV1, ETV4). Studies show that ETS 
fusions are associated with a worse prognosis while other 
studies correlate with improved outcomes [5].
MicroRNAs (miRNAs) are 18–22 nucleotide 
noncoding regulatory RNAs which play a key regulatory 
role in gene expression at the posttranscriptional level 
[12]. In cancer, miRNA expression profiles have been 
found to be tissue type-specific and have been shown to 
be oncogenic or tumor-suppressors, implicating them as 
key regulators of cancer biology [13]. However, only a 
few reports exist in the literature describing the role of 
miRNAs in PCa aggressiveness and racial disparities [14]. 
miR-34b belongs to the miR-34 family of miRNAs: miR-
34a, miR-34b, and miR-34c. miR-34b and miR-34c share 
a primary transcript on chromosome 11q23, whereas miR-
34a is located at 1p36 and is encoded in its own transcript 
[15]. All of these miRNAs share the same seed sequence 
having similar endogenous mRNA targets. Promoter 
regions of mir-34a and mir-34b/c contain a match to the 
canonical p53 binding site and are direct p53 targets, 
which induce apoptosis, cell cycle arrest and senescence 
[16, 17]. miR-34b is a well-described tumor suppressor in 
a number of malignancies including colorectal, pancreatic, 
mammary, ovarian, urothelial, renal cell carcinomas 
and soft tissue sarcomas [18]. In the current study, we 
demonstrate that low miR-34b expression is responsible 
for aberrant expression of AR associated with prostate 
cancer progression and aggressiveness, especially among 
African-American men.
RESULTS
Lower expression of miR-34b in an African-
American prostate cancer cell line and tissue 
samples compared to Caucasians
To investigate if miR-34b expression could 
potentially be associated with biological differences 
between African-American and Caucasian prostate 
cancer, tumors samples were collected from 81 African-
American and 62 Caucasian patients with localized 
disease. Clinicopathologic information is summarized in 
Supplemental Table 1. Expression analysis of miR-34b 
by qRT-PCR revealed that this miRNA was significantly 
correlated with race using Fisher’s exact test (p=0.03) 
in African-American samples compared to Caucasian 
samples (Figure 1A). Also, analysis from Taylor data 
indicated that prostate tumor samples express lower level 
of miR-34b compared to normal samples (Figure 1B). 
In order to mimic the tissue sample results and help us 
identify mechanisms related to racial disparity, we selected 
two cell lines, DU-145 and MDA-PCa-2b, which express 
different levels of miR-34b. The African-American cell 
line, MDA-PCa-2b, expresses significantly lower amounts 
of miR-34b-3p compared to Caucasian cell line, DU-145 
(Figure 1C).
miR-34b overexpression decreases the cell 
viability of an African-American cell line more 
than Caucasian cell line
To determine the role played by miR-34b in 
differences between African-Americans and Caucasians, 
miR-34b was overexpressed in MDA-PCa-2b and DU-
145 cells. We confirmed increased miR-34b expression 
by qRT-PCR after transfection of miR-34b-3p mimic 
(Figure 1D, 1F). We performed cell viability assays and 
found decreased cell viability in MDA-PCa-2b and DU-
145 cells compared with negative control. Interestingly, 
the decrease in cell viability by miR-34b-3p mimic 
was more significant in MDA-PCa-2b (p=0.003) than 
DU-145 (p=0.03), suggesting that miR-34b has a more 
potent effect on the African-American cell line (Figure 
1E, 1G).
Chromosomal deletion in miR-34b in MDA-
PCA-2b cell line
The Cancer Genome Atlas (TCGA) data portal 
(https://tcga-data.nci.nih.gov/tcga/) was used to validate 
differences in DNA hypermethylation of the miR-34b-
3p promoter region and it showed significantly higher 
methylation in prostate cancer compared to normal 
samples (Supplemental Figure 1A). We then treated 
MDA-PCa-2b and DU-145 cell lines with 5-AZA-CdR 
and found no change in the expression of miR-34b in DU-
145 or MDA-PCa-2b cells (Supplemental Figure 1B). We 
analyzed the relationship of miR-34b-3p chromosomal 
abnormality with the cBioPortal web tool for exome 
analysis data. These data showed that miR-34b was deleted 
in 3.4% of prostate adenocarcinoma patients (5/149) from 
the Nelson Lab at the Fred Hutchinson Cancer Research 
Center, 1.5% (5/332) of prostate adenocarcinomas from 
the TCGA database and 0.7% (1/150) of metastatic 
prostate cancers from a published article [20]. We then 
sequenced the promoter region of miR-34b-3p and found a 
chromosomal deletion in miR-34b in MDA-PCA-2b cells 
but not in DU-145 cells (Supplemental Figure 2).
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Figure 1: miR-34b expression in prostate cancer patients and cell viability in prostate cancer cell lines. A. qPCR analysis 
for miR-34b-3p expression in Caucasians (CaA, n=62) and African-Americans (AfA, n=81) normalized by RNU48 (p<0.03). B. analysis of 
miR-34b levels on normal (N) and prostate tumor samples (T) from Taylor data. C. qPCR analysis for miR-34b-3p expression in DU-145 
and MDA-PCa-2b cell lines. Bar=±SE. p-value was calculated by two-tailed t-test. D and F. MDA-PCa-2b cells or DU-145, respectively, 
were transfected with miR-34b-3p mimic for 72h and miR-34b-3p expression was evaluated by Taqman analysis. E and G. Cell viability 
for MDA-PCa-2b or DU-145, respectively, was measured using CellTiter-Glo assay and is shown as the relative cell number compared with 
control cells. Bar=±SE. p-value was calculated by two-tailed t-test.
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African-American and Caucasian prostate 
cancer cells have differences in apoptosis and cell 
cycle regulation
After overexpression of miR-34b-3p, the fraction 
of cells undergoing apoptosis was quantified by using 
Annexin V/7AAD staining. Both cell lines, MDA-PCa-
2b and DU-145, transfected with miR-34b-3p showed a 
significantly increased apoptosis compared to negative 
control. DU-145 transfected cells showed 3 fold increases 
of apoptosis compared to control, while MDA-PCa-2b 
showed 5 fold increases of apoptosis, suggesting that miR-
34b induces a higher apoptosis rate in African-American 
compared to Caucasian cells (Figure 2A-2B).
The cell cycle profile of MDA-PCa-2b and DU-
145 cell lines overexpressed with miR-34b-3p showed 
an increase in the G1 phase (MDA-PCa-2b, NC 54.4% 
compared to miR-34b-3p transfected cells 74.7); (DU-
145, NC 72.9% vs miR-34b-3p transfected cells 82.8%) 
suggesting that miR-34b-3p can induce G1 arrest in these 
cells lines (Figure 2C and 2E). Based on our Western blot 
results, DU-145 cells transfected with miR-34b-3p showed 
high expression of p21Cip1, p27Kip1, both involved in the 
regulation of cell cycle G1 arrest (Figure 2D). Interesting, 
MDA-PCa-2b cells transfected with miR-34b-3p did not 
show on increase in p21Cip1, p27Kip1 expression, suggesting 
that regulation of the cell cycle in these cells lines occurs 
by another mechanism (Figure 2F). Since MDA-PCa-
2b cells have miR-34b-3p deletion, this may be a factor 
causing the difference in cell cycle regulation.
PCR array analysis
PCR array analysis was performed to determine the 
molecular effects of miR-34b overexpression in MDA-
PCa-2b and DU-145 cells. Of the 84 genes represented 
in the Human Prostate Cancer RT2 Profiler PCR Array 
PAHS-135Z (Qiagen), heat map shows the expression 
levels of genes in MDA-PCA-2b or DU-145 cells after 
transfection with miR-34b-3p mimic (Figure 3A). These 
downregulated genes belong to 19 different pathways, 
including the androgen receptor and insulin signaling 
pathways (Table 1). From the genes downregulated 
in MDA-PCa-2b upon miR-34b transfection, we used 
miRwalk, TargetScan, miRanda and RNA22 to predict 
potential miR-34b binding sites and selected AR, BcL2, 
ETV1, NRIP1, PDPK1, PPP2R1B, SCAF11 and SFRP1 
genes for further studies (Figure 3B).
AR and ETV1 expression are regulated by  
miR-34b
We performed lentiviral vector-mediated expression 
of miR-34b in MDA-PCa-2b and DU-145 cells and 
subsequently we performed real-time PCR to validated 
differently expressed genes identified by PCR array 
analysis. Real-time PCR confirmed that 4 genes (AR, 
BcL2, ETV1 and PDPK1) with miR-34b binding site 
were downregulated in MDA-PCA-2b cells transfected 
with miR-34b mimic (Figure 4A). Western blot 
analysis showed that AR and ETV1 were significantly 
downregulated in miR-34b-3p MDA-PCa-2b transfected 
cells. Interestingly, miR-34b overexpression also caused 
a significant downregulation of IGF1 expression, at RNA 
and protein levels, in MDA-PCa-2b but not DU-145 cells 
(Figure 4A and 4B). Although IGF1 is not predicted to 
have a miR-34b binding site, IGF1 is closely related to 
the AR pathway and is one of the pathways that were 
significantly altered upon miR-34b overexpression in our 
pathway analysis (Table 1).
Also, luciferase reporter assay showed a 
significantly lower level of luciferase activity in miR-34b 
stably expressed HeLa cells when cells were transfected 
with the miR-34b binding site containing vectors, 
indicating a direct interaction between miR-34b and AR 
or ETV1 expression (Figure 4C).
Level of AR inversely correlates with miR-34b
To determine whether our findings have clinical 
relevance, we examined the relationship between AR 
with miR-34b levels in the Caucasian and African-
American FFPE samples by IHC. We found that protein 
level of AR is higher in African-American compared to 
Caucasian (Figure 5A and 5B). Interestingly, level of AR 
in African-American samples inversely correlates with 
miR-34b expression (Figure 5C). These indicate that our 
clinical data demonstrate that miR-34b correlates with 
AR expression and are associated with aggressiveness of 
prostate cancer in African-American males.
DISCUSSION
It is well-known that miRNAs play a central role in 
the regulation of gene expression and miR-34b has been 
reported to be a tumor suppressor in many types of cancers 
[18, 21]. In this study, we provide novel insight into the 
role and regulation of miR-34b in African-American and 
Caucasian prostate cancer.
We report that miR-34b expression is lower in 
African-American prostate tumor samples compared 
to Caucasians. Analyzing 143 prostate tumors from 
81 African-American and 62 Caucasian patients, we 
identified a significant loss of miR-34b in African-
American compared to Caucasian samples (Figure 1). We 
also found that miR-34b directly controls transcription of 
AR and ETV1 leading to cell death.
The expression of miR-34b and miR-34c is low 
across all prostate cancers, due to allelic deletions and/
or the loss of heterozygosity that frequently occurs at 
11q23 [22]. Also, miR-34b can be epigenetically regulated 
through promoter hypermethylation in some prostate 
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Figure 2: Effects of miR-34b overexpression on cell cycle and apoptosis of MDA-PCa-2b and DU-145 cells. MDA-PCa- 
2b and DU-145 cells were transfected with miR-34b mimic or negative control. A and B. Apoptosis in MDA-PCa-2b and DU-145 cells, 
respectively, were measured by flow cytometric analysis of cells labeled with Annexin-V/7AAD double staining. C and D. Cell cycle 
distribution of MDA-PCa-2b and DU-145 cells, respectively, was analyzed by propidium iodide staining by flow cytometry. D and F. 
Immunoblot analysis in MDA-PCa-2b and DU-145 cells, respectively, for p21 and p27 expression.
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Figure 3: Gene expression changes in MDA-PCa-2b and DU-145 cells transfected with miR-34b-3p mimic was analyzed 
using RT2 Profiler PCR Array. A. heatmap of genes with altered expression. Up-regulated genes are in red and down-regulated genes 
are in blue. B. down-regulated genes in MDA-PCa-2b upon miR-34b overexpression with potential miR-34b binding sites.
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cancer cell lines and human tumor specimens. We found 
miR-34b chromosomal loss in MDA-PCa-2b but not in 
DU-145 cells (Supplemental Figure 2). Further analysis 
in additional tumor samples is necessary to fully elucidate 
the deletion of miR-34b in African-American patients.
In order to identify pathways and genes relevant 
to racial disparity, gene expression profiling analysis 
was performed using a prostate cancer pathway-focused 
PCR array with miR-34b transfected DU-145 and MDA-
PCa-2b cells. Expression profiling of 84 genes showed 
that several genes were downregulated upon miR-34b 
overexpression in MDA-PCa-2b cells when compared 
to DU-145 transfected cells (Figure 3). Prediction based 
on TargetScan, miRwalk, RNA22 and miRanda analysis 
suggested that AR, BcL2, ETV1 and PDPK1 genes could 
be direct targets for miR-34b since it has a seed region 
able to bind to the 3’-UTR of these genes. Luciferase 
assay results clearly indicate that miR-34b regulates AR 
and ETV1 by direct binding to 3’-UTR of mRNA leading 
to translational repression (Figure 4C). The role of AR in 
the development and progression of prostate cancer has 
increased interest in this nuclear receptor [8]. Previous 
studies have shown that by integrating gene expression 
profiling and pathway analyses, multiple components 
within the AR signaling pathway have been shown to be 
upregulated in African-American prostate cancer [23]. 
Our PCR array analysis showed that AR was significantly 
downregulated in MDA-PCA-2b cells transfected with 
miR-34b compared with control. Although DU-145 cells, 
which express high levels of miR-34b, do not express 
AR, we examined the relationship between AR and miR-
34b levels in Caucasian and African-American FFPE 
samples by IHC to determine whether our findings have 
clinical relevance. We found that AR protein levels are 
higher in African-American compared to Caucasian tissue 
samples (Figure 5A and 5B). Moreover, our study found 
low expression of miR-34b in African-American tissue 
samples compared to Caucasians, and its expression was 
inversely correlated with AR staining (Figure 1 and 5). 
This may explain the higher risk of aggressive prostate 
cancer in African-American men. In agreement, Yang et al. 
[24] suggested that AR-FL and AR-V7 activation mediated 
by hnRNPH1 in both a ligand-dependent and independent 
manner in African-Americans may confer prostate cancer 
progression. Also, it is reported that upregulation of PI3K/
AKT, Wnt/B-catenin and IGF1 signaling pathways may 
contribute to activation of AR signaling and aggressiveness 
in African-American prostate cancer [23, 25]. Other 
Table 1: Pathway analysis for down-regulated genes in MDA-PCA-2b cells transfected with miR-34b-3p mimic
Pathway size candidates p-value q-value source
Prostate cancer - Homo sapiens (human) 89 11 (12.4%) 1.E-13 7.E-11 KEGG
AMPK signaling pathway - Homo sapiens (human) 124 11 (8.9%) 5.E-12 1.E-09 KEGG
Pathways in cancer - Homo sapiens (human) 398 15 (3.8%) 1.E-10 2.E-08 KEGG
Integrated Pancreatic Cancer Pathway 170 11 (6.5%) 2.E-10 2.E-08 Wikipathways
Nongenotropic Androgen signaling 31 6 (19.4%) 4.E-09 5.E-07 PID
Coregulation of Androgen receptor activity 61 7 (11.5%) 8.E-09 8.E-07 PID
IGF signaling 36 6 (16.7%) 1.E-08 9.E-07 INOH
AMPK Signaling 68 7 (10.3%) 2.E-08 1.E-06 Wikipathways
SREBP signalling 68 7 (10.3%) 2.E-08 1.E-06 Wikipathways
Endometrial cancer - Homo sapiens (human) 52 6 (11.5%) 1.E-07 6.E-06 KEGG
Androgen receptor signaling pathway 89 7 (7.9%) 1.E-07 6.E-06 Wikipathways
mTOR signaling pathway - Homo sapiens (human) 60 6 (10.0%) 2.E-07 1.E-05 KEGG
Angiogenesis overview 61 6 (9.8%) 3.E-07 1.E-05 Wikipathways
Integrated Breast Cancer Pathway 64 6 (9.4%) 4.E-07 1.E-05 Wikipathways
human cytomegalovirus and map kinase pathways 16 4 (25.0%) 6.E-07 2.E-05 BioCarta
Ghrelin 39 5 (12.8%) 7.E-07 3.E-05 NetPath
insulin 78 6 (7.7%) 1.E-06 4.E-05 INOH
Interleukin-11 Signaling Pathway 44 5 (11.4%) 1.E-06 4.E-05 Wikipathways
insulin Mam 82 6 (7.3%) 2.E-06 5.E-05 INOH
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studies show that IGF1 can activate AR by activating the 
PI3K/AKT pathway under low or absence of androgen 
levels [25–27]. Fan et al. [28] showed a positive feedback 
regulatory loop between AR and IGF1 that enhances AR 
activation, suggesting that pharmacological strategies that 
reduce IGF1 in combination with antiandrogen therapies 
may have clinical benefit in fighting prostate cancer. AR is 
a master regulator of the downstream androgen-dependent 
signaling pathway and suppresses the AKT pathway 
through FKBP5 and cyclin D1 leading to G1 cell cycle 
arrest [29, 30].
ETV1 is overexpressed in many prostate tumors and 
is associated with a higher Gleason score in aggressive 
prostate tumors [31–33]. Cai et al. [31] reported that 
ETV1 is an androgen receptor regulated gene that 
mediates prostate cancer cell invasion. Other studies 
show that ETV1 interacts and cooperates with AR 
signaling by favoring activation of the AR transcriptional 
program [5, 33]. Our study showed upregulation of AR 
in African-Americans when compared to Caucasian tissue 
samples (Figure 5A and 5B). We also observed inverse 
correlation of miR-34b and AR expression in our African-
Figure 4: miR-34b target genes and luciferase reporter assay. A. qPCR analysis of AR, BCL2, ETV1, PDPK1 and IGF1 from 
MDA-PCa-2b or DU-145 cells transfected with miR-34b-3p mimic. Asterisks indicate a p-value <0.05, calculated by two-tailed t-test. B. 
ETV1, IGF1 and AR levels were assessed by Western blot analysis. C. miR-34b binding sites in AR and ETV1 3′-UTR mediate the down-
regulation of AR and ETV1 protein expression by miR-34b. p-value was calculated by two-tailed t-test.
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American tissue samples, suggesting that our clinical 
data demonstrate that miR-34b and AR are associated 
with aggressiveness of African-American prostate cancer 
(Figure 5C).
Importantly, the field of RNA therapeutics is 
currently undergoing a major expansion and miRNA-
based therapies have already entered into clinical 
trials. miR-34 mimic (MRX34) has become the 
first microRNA to reach phase 1 clinical trials for 
hepatocellular carcinoma and chronic lymphocytic 
leukemia [34–37]. This phase 1 clinical trial represents 
an important step forward not only for miR-34 but is 
valuable proof of principle for the rationale of using 
miRNAs as anticancer drugs [37]. Further investigations 
are warranted to evaluate the potential of miR-34b in 
preclinical and clinical settings for prostate cancer and 
race disparities.
In summary, we have demonstrated that miR-34b 
expression is lower in African-American compared to 
Caucasian tissue samples and is inversely correlated with 
high AR level leading to cell proliferation and cancer 
progression. We concluded that miR-34b and AR play 
a pivotal role in the treatment of aggressive African-
American prostate cancers.
Figure 5: Staining pattern of AR in prostate cancer. A and B. African-American and Caucasian tissue samples, respectively, were 
stained with AR. Original magnifications: × 200, scale bars: 500μm. C. Quantification of AR expression on African-American (Afa) and 
Caucasian (CaA) analyzed by IHC. D. Inverse correlation between the expression of AR protein analyzed by IHC and miR-34b analyzed 
by qPCR.
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MATERIALS AND METHODS
Patient samples and cell lines
Human prostate cell lines MDA-PCa-2b, DU-145 
were obtained from the American Type Culture Collection. 
The Caucasian derived cell line, DU-145, was maintained 
in RPMI-1640 with 10% FBS and the African-American 
derived cell line, MDA-PCa-2b, was cultured in HPC1 
with 20% FBS in Poly-L-Lysine (Sigma–Aldrich) coated 
culture dishes. Culture medium was supplemented with 
antibiotics and cells were cultured at 37°C with 5% CO2. 
African-Americans (n=41) and Caucasians (n=62) clinical 
FFPE (Formaldehyde Fixed Paraffin Embedded) samples 
were obtained from the Veterans Affair Medical Center, 
San Francisco, CA, USA. Additional African-American 
samples (n=40) were obtained from National Disease 
Research Interchange. Also, we used miRNA expression 
data from the Taylor data that is available at the Gene 
Expression Omnibus (GEO accession number: GSE21032).
Transient transfection
In order to induce miR-34b-3p expression, cells 
were transfected with a mirVana miR-34b-3p Mimics 
(Thermo Fisher Scientific) using Lipofectamine RNAi 
Max (Thermo Fisher Scientific). To verify the transfection 
effect of miRNA mimics, mirVana miRNA Mimic 
Negative Control #1 (Thermo Fisher Scientific) was 
included in each transfection experiment.
Cell cycle analysis
Transfected cells were harvested using Accutase 
(Corning), washed with cold PBS and fixed in cold 70% 
ethanol overnight at -20°C. Cell pellets were stained with 
PI/RNase Staining Buffer (BD Pharmingen) and incubated 
for 15 minutes at room temperature in the dark. Cells were 
analyzed for DNA content by gating excluding doublet 
cells on BD FACSVerse (BD Pharmingen).
Apoptosis assay
Cells were transfected with miR-34b-3p mimic or 
negative control and harvested at different time points. 
Cells were washed in cold PBS, resuspended in 1x binding 
buffer and stained with Annexin V-FITC and 7AAD 
viability dye (Annexin V-FITC/7AAD kit, Beckman 
Coulter). After 15 minutes incubation at room temperature 
in the dark, cells were washed and analyzed using BD 
FACSVerse (BD Pharmingen).
Western blot analysis
Cells were lysed with NP-40 (Thermo Scientific) 
plus Halt Protease and Phosphatase Inhibitor Cocktail 
(Thermo Scientific). Protein concentration was determined 
using BCA Protein Assay (Thermo Fisher Scientific). 
Western blots were performed using NuPAGE 4-12% 
Bis-Tris Protein Gels (Invitrogen). Gels were run in MES 
buffer (Invitrogen) and transferred onto nitrocellulose 
transfer membrane using iblot2 Dry Blotting System 
(Invitrogen). Membranes were incubated with Odyssey 
blocking buffer (Li-Cor) prior to incubation with primary 
antibodies overnight at 4°C. The following primary 
antibodies were used: AR (Cell Signaling, 5153), ETV1 
(Thermo Fisher Scientific, PA5-41484), IGF1 (Thermo 
Fisher Scientific, PA5-27207), p21 (Cell Signaling, 2946), 
p27 (Cell Signaling, 2552), and ß-actin (Cell Signaling, 
3700). Goat anti-rabbit IgG (H+L) 800 CW or goat anti-
mouse (H+L) 680RD was applied for 45 minutes at room 
temperature (1: 15000, LI-COR) prior to washing with 
PBS containing Tween 20. Blots were imaged using an 
Odyssey Infrared Imaging System Scan and quantification 
was carried out with the LI-COR Odyssey® scanner and 
software (LI-COR Biosciences).
Cell viability assay
Cell viability was determined using a CellTiter-Glo 
luminescent cell viability assay (Promega) according to the 
manufacturer’s instructions. Measurements were performed 
every 24 hours for 6 days after transfections of miR-34b-3p 
mimics or negative control (Thermo Fisher Scientific) using 
a Victor X2 microplate reader (PerkinElmer).
Quantitative real-time reverse transcription–
polymerase chain reaction
Total RNA was isolated using a miRNeasy mini 
kit (Qiagen) and reverse-transcribed into cDNA with the 
SuperScript III kit (Life Technologies). Real-time reverse 
transcription–polymerase chain reaction (RT–PCR) was 
performed with SYBR Green (Applied Biosystems) 
using a Quant Studio 7 PCR System. Primer sequences 
are provided in Supplementary Table 2. For miR-34b-3p 
expression analysis, cDNA was synthesized from total 
RNA with TaqMan Reverse Transcription kit (Applied 
Biosystems) with specific primers and the cDNA was 
subjected to Taqman Probe-based Real Time PCR using 
and TaqMan miRNA assays Universal PCR Master Mix 
(Thermo Fisher Scientific) according to the manufacturer’s 
instructions. The expression levels of miRNA were 
calculated as the amount of target miRNA relative to that of 
RNU48 control to normalize the initial input of total RNA.
RT2 profiler PCR array analysis
Prostate cancer pathway-focused gene expression 
profiling was done using a 96-well human RT2 Profiler 
PCR Array PAHS-135Z (Qiagen). In this array, 84 genes 
were analyzed based on SYBR-Green real-time PCR. 
cDNA was synthesized from MDA-PCa-2b and DU-
145 cells transfected with miR-34b-3p mimic using RT2 
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First Strand Kit (Qiagen) following the manufacturer’s 
instructions. SYBR-Green real-time PCR was performed 
by following the manufacturer’s instructions and fold-
change calculations were accomplished using RT2 
Profiler PCR Array Data Analysis (http://pcrdataanalysis.
sabiosciences.com/pcr/arrayanalysis.php, Qiagen).
Heat mapping and pathway analysis
All expression data obtained from RT2 Profiler 
PCR Array Data were calculated as the logarithm of each 
gene expression value and processed by global median 
centering normalization. Pathway mapping was done 
using R package “pathview” [19].
Viral miRNA induction
Cells were infected with lentivirus containing either 
miR-34b-3p or empty in pmiR-lenti plasmid (Abm) 
to generate stable miR-34b-3p expression clones after 
growing with puromycin containing media (5μg/ml) for 
two weeks. Viral vectors were packaged by co-transfection 
into HEK293T9 cell line with pMD.2G and pPAX2 kindly 
obtained from Dr. Didier Trono.
Immunohistochemical on human samples
Immunohistochemical (IHC) staining was 
performed in Caucasian and African-American prostate 
cancer specimens using Lab Vision™ UltraVision™ 
Detection System (Thermo Scientific). AR (Cell Signaling, 
5153) was diluted 1:400 in 5% normal goat serum (Cell 
Signaling) and incubated overnight at 4°C. Brown color 
in DAB-stained IHC images were quantified using color 
deconvolution in ImageJ.
Luciferase promoter assay and 3’-UTR 
luciferase reporter
For reporter assays, we used stable clones of HeLa 
cells that were established by viral infection with miR-
34b or empty vector and transfected into each stable clone 
with miR-34b binding site containing luciferase reporter 
vectors. The sequences of the cloning primers are shown 
in Supplementary Table 2. Firefly luciferase activities were 
measured using Dual Luciferase Assay (Promega) after 
transfection and results normalized with Renilla luciferase.
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